Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit

被引:69
作者
Rebuck, JA
Fish, DN
Abraham, E
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Denver, CO 80262 USA
[2] Univ Vermont, Dept Pharmacotherapy, Fletcher Allen Hlth Care, Burlington, VT USA
[3] Univ Vermont, Dept Surg & Trauma Crit Care, Burlington, VT USA
[4] Univ Colorado, Hlth Sci Ctr, Sch Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA
来源
PHARMACOTHERAPY | 2002年 / 22卷 / 10期
关键词
D O I
10.1592/phco.22.15.1216.33484
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To characterize the pharmacokinetic disposition of intravenous and oral levofloxacin in critically ill adults. Design. Prospective, open-label study. Setting. University teaching hospital. Patients. Thirty critically ill patients in a medical intensive care unit (ICU). Interventions. All patients received levofloxacin as part of their routine medical care. Pharmacokinetic evaluations were performed in 28 patients receiving intravenous levofloxacin. Ten of these patients subsequently were switched to oral levofloxacin and underwent a second pharmacokinetic evaluation during oral therapy. Measurements and Main Results. Mean +/- SD levofloxacin half-life, clearance at steady state, and volume of distribution in all 28 patients were 8.0 +/- 1.7 hours, 134 +/- 35 ml/minute, and 1.2 +/- 0.3 L/kg, respectively Maximum and minimum serum concentrations (C-max and C-min) and area under the serum concentration-time curve from 0-24 hours (AUC(0-24)) in patients receiving levofloxacin 500 mg intravenously were 7.5 +/- 0.8 mg/L, 1.0 +/- 0.5 mg/L, and 66.1 +/- 15.7 mg.hour/L, respectively. Observed C-max, C-min, and time at which maximum concentration was achieved after oral doses of levofloxacin 500 mg were 5.5 +/- 1.1 mg/L, 0.8 +/- 0.4 mg/L, and 1.3 0.4 hours, respectively These values were significantly different (p<0.05) from those observed after intravenous dosing in the same patients; other pharmacokinetic parameters were similar. Statistically significant increases (p<0.05) in C-max, C-min, half-life, and AUC(0-24) were found in critically ill patients administered multiple doses of intravenous levofloxacin compared with historical data from healthy volunteers. Conclusions. The dosage regimen of intravenous levofloxacin 500 mg once/day appears adequate for most pathogens found in critically ill patients with normal renal function. Less susceptible pathogens may require an increased daily dose for more optimal therapy. Orally administered levofloxacin appears to be well absorbed in selected ICU patients and has pharmacokinetics similar to those of intravenously administered levofloxacin.
引用
收藏
页码:1216 / 1225
页数:10
相关论文
共 31 条
  • [1] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections
    Ambrose, PG
    Grasela, DM
    Grasela, TH
    Passarell, J
    Mayer, HB
    Pierce, PF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) : 2793 - 2797
  • [2] Sequential parenteral and oral ciprofloxacin regimen versus parenteral therapy for bacteremia: A pharmacoeconomic analysis
    AmodioGroton, M
    Madu, A
    Madu, CN
    Briceland, LL
    Seligman, M
    McMaster, P
    Miller, MH
    [J]. ANNALS OF PHARMACOTHERAPY, 1996, 30 (06) : 596 - 602
  • [3] BERDEAUX D, 2002, 10 INT C INF DIS SIN
  • [4] THE ALTERED PHARMACOKINETICS AND PHARMACODYNAMICS OF DRUGS COMMONLY USED IN CRITICALLY ILL PATIENTS
    BODENHAM, A
    SHELLY, MP
    PARK, GR
    [J]. CLINICAL PHARMACOKINETICS, 1988, 14 (06) : 347 - 373
  • [5] Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995
    Brueggemann, AB
    Coffman, SL
    Rhomberg, P
    Huynh, H
    Almer, L
    Nilius, A
    Flamm, R
    Doern, GV
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 680 - 688
  • [6] Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects
    Chien, SC
    Chow, AT
    Natarajan, J
    Williams, RR
    Wong, FA
    Rogge, MC
    Nayak, RK
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) : 1562 - 1565
  • [7] Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses
    Chien, SC
    Rogge, MC
    Gisclon, LG
    Curtin, C
    Wong, F
    Natarajan, J
    Williams, RR
    Fowler, CL
    Cheung, WK
    Chow, AT
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) : 2256 - 2260
  • [8] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [9] A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
    File, TM
    Segreti, J
    Dunbar, L
    Player, R
    Kohler, R
    Williams, RR
    Kojak, C
    Rubin, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) : 1965 - 1972
  • [10] The clinical pharmacokinetics of levofloxacin
    Fish, DN
    Chow, AT
    [J]. CLINICAL PHARMACOKINETICS, 1997, 32 (02) : 101 - 119